<div id="readability-page-1"><div id="article-body-row"> <div> <p dir="ltr">Ro is bringing Serena Williams to the Super Bowl.</p> <p dir="ltr">Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam winner’s life changed after taking GLP-1 drugs sourced from the telehealth company.</p> <p dir="ltr">Williams first spoke about her experience on GLP-1s in an ad in August, explaining how she began using Ro and the medicine to lose weight after the birth of her second daughter. After finding it all but impossible to lose weight through exercise alone, Williams shed 31 pounds over eight months while taking GLP-1s. Ro used Williams’ experience to argue that willpower alone can be insufficient when trying to lose weight.   </p>   <p dir="ltr">During the Super Bowl LX broadcast on Feb. 8, Ro and Williams will deliver their message to the biggest TV audience of the year. The 30-second ad, which Ro unveiled Wednesday, starts with Williams saying, “I’m on Ro,” in a voiceover as the camera pulls back from a close-up of the tennis star to show the company’s logo in the background. </p> <p dir="ltr">The rest of the ad features updates on Williams’ health over footage showing that she is “moving better on Ro,” joining other GLP-1 sellers in shifting focus from cosmetic to health changes that occur with the obesity and diabetes drugs. After one year, Williams has lost 34 pounds, lowered her cholesterol by 30% and cut her lifetime risk of heart disease by a relative 70%. Ro noted that several of Williams’ health markers are better now than they were at the end of her career as a professional athlete.</p> <p dir="ltr">Williams lost weight on an injectable GLP-1 drug, though, as she notes in the ad, a GLP-1 weight-loss pill is now available. Ro began selling Novo Nordisk’s Wegovy pill amid its rollout earlier this month.</p>   <p dir="ltr">Ro’s Super Bowl ad is the centerpiece of a broader marketing push, according to Wednesday's announcement. The company is launching a national advertising strategy spanning linear and broadcast TV, paid social and out-of-home takeovers across the U.S. </p> <p dir="ltr">While Williams is the sole star of the Super Bowl ad, she is one of several faces in the broader marketing drive. Fellow Ro GLP-1 patient ambassador Charles Barkley, who lost 45 pounds in seven months, is also part of the campaign. Ro introduced Barkley as an ambassador last April, in an ad in which the NBA Hall of Famer set out his ambition to lose 65 pounds.</p> <p dir="ltr">The celebrity ambassadors are joined in the campaign by Hannah Nylander-Asplin, Deanna and Mitchell Taylor and Greg Olson, with Ro saying it will “highlight the stories of its everyday patients with the same level of authenticity as its celebrity ambassadors.”</p> <p>Ro’s 2026 Super Bowl ad joins other new commercials from the likes of Boehringer Ingelheim and also follows in the footsteps of fellow telehealth company Hims &amp; Hers, which secured airtime at last year's event to talk GLP-1s and sparked quite the controversy in the process. While Ro’s ad references FDA-approved drugs and Novo’s oral GLP-1 medicine, Hims &amp; Hers criticized the pharma industry for selling drugs “priced for profits, not patients,” earning ire from many angles.</p>  </div> </div></div>

ROIV

<p>Ro is set to air a Super Bowl ad featuring Serena Williams, highlighting her weight loss journey with GLP-1 drugs. The ad showcases Williams' transformation, including a 34-pound weight loss and improved health markers. Ro's campaign aims to shift the narrative around GLP-1s from cosmetic to health benefits. Alongside Williams, other ambassadors like Charles Barkley will also feature in the broader marketing strategy. The ad is part of Ro's national advertising push, which includes various media platforms, and follows similar efforts by other telehealth companies.</p>

Ro serves up Super Bowl GLP-1 ad starring Serena Williams